

Pamela M Pollock

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1638668/pamela-m-pollock-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62
papers

9,486
citations

35
h-index

66
g-index

66
ext. papers

11,040
ext. citations

10.5
avg, IF

5.13
L-index

#	Paper	IF	Citations
62	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013 , 497, 67-73	50.4	2800
61	Molecular classification of cutaneous malignant melanoma by gene expression profiling. <i>Nature</i> , 2000 , 406, 536-40	50.4	1647
60	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003 , 33, 19-20	36.3	1355
59	Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. <i>Cancer Research</i> , 2005 , 65, 6282-93	10.1	261
58	Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. <i>Oncogene</i> , 2007 , 26, 7158-62	9.2	254
57	Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. <i>Nature Genetics</i> , 2003 , 34, 108-12	36.3	223
56	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015 , 28, 836-44	9.8	222
55	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6146-53	12.9	195
54	Microarray expression profiling in melanoma reveals a BRAF mutation signature. <i>Oncogene</i> , 2004 , 23, 4060-7	9.2	159
53	Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. <i>Genes Chromosomes and Cancer</i> , 1996 , 15, 77-88	5	133
52	A genome-based strategy uncovers frequent BRAF mutations in melanoma. <i>Cancer Cell</i> , 2002 , 2, 5-7	24.3	128
51	Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. <i>Cancer Research</i> , 2008 , 68, 6902-7	10.1	124
50	FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. <i>PLoS ONE</i> , 2012 , 7, e30801	3.7	122
49	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3388-3397	2.2	116
48	Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. <i>Molecular Cancer Research</i> , 2009 , 7, 41-54	6.6	100
47	The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. <i>Neoplasia</i> , 2013 , 15, 975-88	6.4	98
46	Targeting mutant fibroblast growth factor receptors in cancer. <i>Trends in Molecular Medicine</i> , 2011 , 17, 283-92	11.5	96

45	Active Notch1 confers a transformed phenotype to primary human melanocytes. <i>Cancer Research</i> , 2009 , 69, 5312-20	10.1	93
44	p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 895-902	6.1	86
43	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>OncImmunity</i> , 2017 , 6, e1264565	7.2	79
42	Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. <i>Oncogene</i> , 1997 , 15, 2999-3005	9.2	74
41	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015 , 2, 671-80	8.8	67
40	A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014 , 135, 38-43	4.9	67
39	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. <i>Oncotarget</i> , 2015 , 6, 17753-63	3.3	65
38	PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. <i>Melanoma Research</i> , 2002 , 12, 565-75	3.3	55
37	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 781-94	4.5	50
36	FGFR2 as a molecular target in endometrial cancer. <i>Future Oncology</i> , 2009 , 5, 27-32	3.6	49
35	Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. <i>Human Mutation</i> , 1998 , 11, 424-31	4.7	49
34	A crystallographic snapshot of tyrosine trans-phosphorylation in action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19660-5	11.5	49
33	Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. <i>Carcinogenesis</i> , 2006 , 27, 1778-86	4.6	49
32	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 1478-92	5.6	46
31	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 117, 125-9	4.9	38
30	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. <i>International Journal of Cancer</i> , 1997 , 73, 531-6	7.5	37
29	XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. <i>Anti-Cancer Drugs</i> , 2013 , 24, 181-8	2.4	36
28	Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. <i>Genes Chromosomes and Cancer</i> , 2004 , 41, 56-64	5	36

27	Homodimerization controls the fibroblast growth factor 9 subfamily B receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. <i>Molecular and Cellular Biology</i> , 2009 , 29, 4663-78	4.8	33
26	Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. <i>Melanoma Research</i> , 2002 , 12, 183-6	3.3	31
25	Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. <i>Molecular Cancer</i> , 2012 , 11, 75	42.1	30
24	Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. <i>Journal of Biological Chemistry</i> , 2011 , 286, 42303-42313	5.4	29
23	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 637-648	6.1	26
22	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017 , 145, 366-373	4.9	26
21	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018 , 31, 1851-1861	9.8	24
20	Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 1517-26	3.5	19
19	The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor. <i>Oncotarget</i> , 2016 , 7, 49677-49687	3.3	18
18	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. <i>American Journal of Human Genetics</i> , 2016 , 98, 1159-1169	11	17
17	Mutation analysis of the CDKN2A promoter in Australian melanoma families. <i>Genes Chromosomes and Cancer</i> , 2001 , 32, 89-94	5	17
16	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. <i>Gynecologic Oncology</i> , 2017 , 146, 327-333	4.9	16
15	Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents. <i>Cancer Discovery</i> , 2015 , 5, 355-7	24.4	15
14	Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. <i>Human Reproduction</i> , 2008 , 23, 1661-8	5.7	12
13	FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. <i>Journal of Cell Science</i> , 2018 , 131,	5.3	11
12	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. <i>Theranostics</i> , 2020 , 10, 2095-2114	12.1	10
11	CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. <i>International Journal of Cancer</i> , 2001 , 93, 361-7	7.5	10
10	Endometrial cancer cells exhibit high expression of p110 α and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , 2017 , 8, 3881-3894	3.3	10

9	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. <i>DNA Repair</i> , 2017 , 54, 30-39	4.3	9
8	Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. <i>Molecular Oncology</i> , 2019 , 13, 738-756	7.9	7
7	Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse. <i>Differentiation</i> , 2017 , 94, 8-20	3.5	6
6	FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2020 , 26, 4569-4580	12.9	3
5	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.. <i>Genome Medicine</i> , 2022 , 14, 3	14.4	2
4	Genomic analysis of patient-derived xenograft models reveals intra-tumor heterogeneity in endometrial cancer and can predict tumor growth inhibition with talazoparib		2
3	Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
2	Lineage-specific biomarkers predict response to FGFR inhibition. <i>Cancer Discovery</i> , 2012 , 2, 1081-3	24.4	1
1	A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. <i>Genomics</i> , 1993 , 18, 733-4	4.3	1